Skip to content

Clinical study of non-invasive biomarker for urothelial carcinoma

Clinical application of urine DNA methylation detection in urothelial carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200066864
Enrollment
Unknown
Registered
2022-12-20
Start date
2022-12-30
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urothelial carcinoma

Interventions

Gold Standard:Cystoscopy, ureteroscopy and related pathological diagnosis are the gold standard or reference standard for accurate diagnosis of bladder cancer, ureteral cancer or renal pelvis cancer,
Index test:Methylation status of the target gene (negative or positive)

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Anyone who meets any of the following conditions can be selected: (1) Aged over 18 years old; patients with bladder cancer and upper urinary tract urothelial cancer (ureteral cancer, renal pelvis cancer) diagnosed by cystoscopy, ureteroscopy and pre-operative biopsy. (2) Aged over 18 years old; admitted to the urology department, patients with common benign urinary system diseases (urinary calculi, hydrops, infection, benign prostatic hyperplasia, cystitis glandularis), and the final diagnosis results are non-bladder cancer and non-bladder cancer; Patients with other urological tumors (kidney cancer, prostate cancer) of upper urothelial carcinoma. (3) The age is over 18 years old; the person who has a normal physical examination in the physical examination center.

Exclusion criteria

Exclusion criteria: Any one of the following conditions can be excluded: (1) Patients with other major diseases, recent surgery or previous malignant tumors. (2) Patients undergoing total cystectomy or radical ureterectomy. (3) Samples not preserved as required.

Design outcomes

Primary

MeasureTime frame
sensitivity;specificity;accuracy;

Countries

China

Contacts

Public ContactLiqun Zhou

Peking University First Hospital

zhoulqmail@sina.com+86 13601239241

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026